ClinicalTrials.gov
public full text
Public Domain
The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease
This study is divided into two phases: a dose-escalation phase and an expansion cohort phase. The dose-escalation phase is a single-center study, while the expansion cohort phase is a multicenter, prospective, randomized, double-blind, placebo-controlled study.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia#1112412
- Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease#864213
- A Phase I Study for Safety and Tolerability of AL002.#851935
- Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia#839417
- Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers#1010091
Record · ID 1164521
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive